What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

Astellas’ fezolinetant isn’t due for an FDA decision until February in vasomotor symptoms (VMS) associated with menopause — but the pharma company isn’t waiting until then to educate women about what’s causing their hot flashes.